We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

POLX Polarean Imaging Plc

0.00 (0.00%)
12 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Polarean Imaging Plc LSE:POLX London Ordinary Share GB00BF3DT583 ORD GBP0.00037
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.00% 3.90 163,703 07:36:58
Bid Price Offer Price High Price Low Price Open Price
3.80 4.00 3.90 3.90 3.90
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Surgical,med Instr,apparatus USD 1.03M USD -13.91M USD -0.0644 -0.61 8.42M
Last Trade Time Trade Type Trade Size Trade Price Currency
16:27:24 O 25,526 3.9175 GBX

Polarean Imaging (POLX) Latest News

Polarean Imaging (POLX) Discussions and Chat

Polarean Imaging Forums and Chat

Date Time Title Posts
12/4/202414:47Polarean Imaging PLC6,524

Add a New Thread

Polarean Imaging (POLX) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type

Polarean Imaging (POLX) Top Chat Posts

Top Posts
Posted at 13/4/2024 09:20 by Polarean Imaging Daily Update
Polarean Imaging Plc is listed in the Surgical,med Instr,apparatus sector of the London Stock Exchange with ticker POLX. The last closing price for Polarean Imaging was 3.90p.
Polarean Imaging currently has 215,848,593 shares in issue. The market capitalisation of Polarean Imaging is £8,418,095.
Polarean Imaging has a price to earnings ratio (PE ratio) of -0.61.
This morning POLX shares opened at 3.90p
Posted at 04/4/2024 13:15 by henley2
Because the CEO is a complete tool.Instead of raising money when first appointed, he's allowed the share price to collapse to where it is today. This will probably either go bust or delist and allow Bracco to take the technology for peanuts. Van Jako gets paid out and Bastien given a lucrative fee to carry on research. Shareholders wiped out! AIMHO
Posted at 04/4/2024 12:31 by goldbutler
The Board of Directors including Bracco representative director and Nukem
said that 9 conversions were planned for 2 years wave 1 and wave 2

Wholly inadequate for the company survival funded by 27 million pounds and more from AIM investors

On a monthly basis 28 people receive a very handsome pay cheque
and the CEO cannot bring himself to refer to shareholders

He never stops on Linkedin including references to a previous company

So where is the investor presentaion for AIM INVESTORS for wave 1 and 2

Wave 1 Wave 2
Ohio Texas
Missouri Iowa
N.Carolina Kansas
Virginia Illinois

Where is the commercial strategy including partnerships for sales into UK and Europe and arab states where there is no shortage of cash and significant COPD problem.

Why would any board of directors behave like this and for 18 months warn and advise of a cash raise and see the share price destruction.
Posted at 04/3/2024 21:59 by goldbutler
The sales forecast from the Board of Directors (including Nukem) is just not good enough.

Polarean in a meeting ( utube 31 mins) feb 23 named 9 existing sites.
-4 for wave one and 5 wave 2 for sales.
That is a total of 9 and they now in their own words give installed forecast for 2025 of 12 maybe 14.

End of 2025

§ Total installed clinical base of 12 to 14 systems

So from years 2023 and 2024 and 2025 they will sell 3.

It simply isn't good enough from a board of directors with Nukem on board with a director running the company.

Have a look at the share price graph why would any board of directors wait until the share price is at the foot of the line graph at 4p to raise funds.

It isn't good enough from this Chairman and Board of Directors and they are not being held to account by UK investors.
Posted at 04/3/2024 16:25 by nigelpm
"An extraordinary 8 months of progress since you took the hot seat"

That made me laugh - remind me where the share price was back then?
Posted at 03/3/2024 21:51 by goldbutler
No Investor presentation - no questions and no answers.
a free run for the Directors.

If 150 million shares are issued and nukem take 50 and Bracco 40 they will end up with just about 35% of the company. Is that by chance or very clever?

is it any wonder that asset managers question the destruction of the share price since the last fund raise back as far as the IPO.
UK Institutional investors need to be more active.

The Chairman and board refuse to market in the UK to NHS or Private Health Care.
They have no difficulty in applying for a UK grant of several million to fund their activity in the USA.

The sales forecast in the USA for the next two years is dreadful.

A reminder that this Chairman and Board of Directors including Nukem are not fit for purpose and are directly responsible for the poor sales forecasts , commercial strategy, commercial traction and the current state of the company and share price.
Posted at 23/2/2024 14:52 by bones698
No deals and no clisomf of the funding gap. Get ready for the surprise or not a surprise fund raise at a discount.

The lack of deals considering how small they usually are is concerning and the share price isnrefelctimg the lack of progress. Meanwhile losses are mounting up and cash fast running out with no sight of break even for years. Left fund raising far too late and pis will pay the price
Posted at 14/2/2024 17:05 by goldbutler
polx 7.0p

The share price graph tells all here.

The stock market value of this company was between 50 - 100 million for many years.

Criticism of 'the market' on this board , was that it didn't know how to value such companies - utter rubbish of course .

The share price graph tells all - it is a reflection of all the players in the market view of the Board of Directors utter failure to use £27million to deliver any commercial traction to date. Investors stung for money by USA based Directors

Brokers figures of sales and equipment in use of 6 then 24 then 48 for the years 21 to 23E have not been delivered by Polarean directors.

In the meantime they and all their employees are paid very well

Asset managers are left wondering not about the technology but about those running the company.

So commercial traction where is it from the Chairman and the CCO Mr Dusek and Mr Brague with his cool $100000 for refining a strategy - which really should have been developed when they had 27million to play with.

Time to deliver Polarean Directors and that means for all shareholders.

Commercial traction and partnerships deals required.
Posted at 12/1/2024 19:26 by goldbutler
polx share p7.5p

It is indeed a concern that Amati see no future in being a shareholder.

The Board of Polarean have had 3 years and 27 million to commercialise and they
have now lost a large shareholder. WHY?

Are they too to be called "NOBODY" by some on this board.

These shareholders funded the company with the working capital to get to this fda approved stage and the utter shambles from BOD since this time last year is a disgrace. The lack of communication is appalling - twice a year and a AGM in the USA.

The new CEO track record is appalling unlike the CEO appointed to destiny Pharma

The share prices reflect this.

The behaviour of the Patel director and shareholder on SHANTA Gold and an offer for that company should give cause for concern to shareholders of Polarean.
Shareholders at Shanta are outraged. Aim and self serving group of directors.

Shareholders own the company not the board of directors

Will Shanta Gold directors behaviour happen at Polarean.
Posted at 15/12/2023 00:12 by w t tutte
@ GoldButter - Why is it worth repeating ? Mr Gerber is a nobody clearly sitting on big losses. Nobody would care about being thanked if we were at 150p share price.

As to disconnect between the technology and the share price I think that is pretty easy to explain.

1) It listed as not much more than an idea and with huge regulatory and capital needs.
2) Richard Huillihan basically worked a miracle in terms of getting all of the elements together and getting it FDA approved.
3) It got swept up in the post pandemic 0% interest retail craze (think Justin Waite and his 100x claims)
4) All those who should never have been in the stock and that includes Amati have now puked it out
5)Buying has yet to return both to the UK small cap space and med tech in particular.

Was listed far too early by "characters" and was only listed in the UK because US investors understood well the regulatory process/risks and hurdles that needed to be overcome.

The irony is that it is now massively derisked and is from a US perspective "investable" but once again UK investors are unable to see it or at very least to grasp the opportunity .... That just means more for you and me.

Probably gets taken out at a ludicrously low price (still multiples of where we sit today)and will prove once again that UK capital markets do not know how to value anything other than Banks, insurance companies, utilities and possibly resources/oil companies.
Posted at 14/12/2023 11:44 by goldbutler
Polx share price 6.75p

The most recent RNS from the BOD refused to thank shareholders - the board of directors and all of their advisers would have reviewed it. The word shareholders was not used at all.
the previous chairman did use the word and meant it.

Amati and others should be pushing for board changes.

The share price has collapsed since the appointment of the new CEO from 26p to 7p and the price this time last year was 54p.

The recent comment from mr gerber on linkedin is worth repeating

Gilbert Gerber
CEO at Belsize Asset Management


I did mind the gap ! Can anybody in board and management reconcile the technology's revolutionary nature with the systematic value destruction since IPO ? As a shareholder of the first hour I truly can't.
Polarean Imaging share price data is direct from the London Stock Exchange

Your Recent History

Delayed Upgrade Clock